Replimune Group Stock (NASDAQ:REPL), Trade Ideas

Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

CMND

IBIO

REPL

TVTX

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday.

The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&amp;P 500 also fell, dropping, 0.07% to 4,566.73.

Crude Oil Moves Lower; AutoZone Profit Tops Views

Movers

ACRV

ALLR

ARCB

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CRMT

DAKT

EYPT

FTCH

GNLX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GTLB

GYRE

HCDI

HSCS

JOAN

LIFW

MMSI

MYNZ

NRSN

SEEL

SOAR

SPHR

SSNT

UCAR

VRPX

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday.

The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&amp;P 500 also fell, dropping, 0.03% to 4,568.46.

Dow Falls 100 Points; ISM Services PMI Increases In November

Replimune Group Inc

REPLENISH NUTRIENTS HLDG by REPLENISH NUTRIENTS HLDG CORP.

Replenish Nutrients Holding Corp

REPLICEL LIFE SCIENCE ORD by RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc

Repligen Corp

Reply SpA

For the full year 2024, we expect:
<ul>
<li>Total revenue of&nbsp;$760&nbsp;to&nbsp;$775 million.</li>
<li>Adjusted EBITDA margin of&nbsp;36%&nbsp;to&nbsp;38%.</li>
<li>Adjusted free cash flow margin in the range of&nbsp;19%&nbsp;to&nbsp;21%&nbsp;of revenue.</li>
<li>Non-GAAP diluted net income per share of&nbsp;$1.60&nbsp;to&nbsp;$1.67.</li>
<li>Fully diluted weighted average shares outstanding of approximately 102 to 103 million shares.</li>
</ul>

Guidance

DOCN

DigitalOcean Holdings Expects FY24 Revenue of $760M-$775M (Prior $755M-$775M) Vs $766.36M Est, Adj EPS of $1.60-$1.67 Vs $1.64 Est

Needham analyst Ryan Koontz maintains Kaltura (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTR#NASDAQ">KLTR</a>) with a Buy and lowers the price target from $5 to $3.

Price Target

Analyst Ratings

KLTR

Needham Maintains Buy on Kaltura, Lowers Price Target to $3

Biotech

Large Cap

Health Care

General

MRNA

Moderna Says That FDA, Due To Administrative Constraints, Does Not Expect To Complete Its Review Of mRNA-1345, Respiratory Syncytial Virus Vaccine, By May 12, The FDA Has Informed Moderna That It Is Working To Conclude The Review By The End Of May

Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) reported quarterly earnings of $1.28 per share which missed the analyst consensus estimate of $1.56 by 17.95 percent. This is a 22.42 percent decrease over earnings of $1.65 per share from the same period last year. The company reported quarterly sales of $493.00 million which beat the analyst consensus estimate of $479.64 million by 2.78 percent. This is a 7.69 percent increase over sales of $457.77 million the same period last year.

Earnings Beats

Earnings Misses

Ubiquiti Q3 Adj $1.28 Misses $1.56 Estimate, Sales $493.00M Beat $479.64M Estimate

Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) reported quarterly losses of $(2.39) per share which missed the analyst consensus estimate of $(2.23) by 7.17 percent.

Instil Bio Q1 2024 GAAP EPS $(2.39) Misses $(2.23) Estimate

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.38 by 10.53 percent. This is a 10.53 percent decrease over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $94.542 million which missed the analyst consensus estimate of $97.895 million by 3.42 percent. This is a 0.71 percent increase over sales of $93.872 million the same period last year.

IIIV

i3 Verticals Q2 2024 Adj EPS $0.34 Misses $0.38 Estimate, Sales $94.542M Miss $97.895M Estimate

Mizuho analyst Vikram Malhorta maintains Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) with a Buy and raises the price target from $56 to $59.

Mizuho Maintains Buy on Realty Income, Raises Price Target to $59

Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) reported quarterly earnings of C$0.92 per share which beat the analyst consensus estimate of C$0.82 by 12.2 percent. This is a 8.24 percent increase over earnings of C$0.85 per share from the same period last year.

Enbridge Q1 2024 Adj EPS C$0.92 Beats C$0.82 Estimate

Wedbush analyst Nick Setyan maintains Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Outperform and lowers the price target from $76 to $65.

PZZA

Wedbush Maintains Outperform on Papa John's International, Lowers Price Target to $65

FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12

Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $0.04 by 2103.25 percent. The company reported quarterly sales of $152.177 million which beat the analyst consensus estimate of $113.850 million by 33.67 percent. This is a 12.16 percent increase over sales of $135.680 million the same period last year.

TSAT

Telesat Q1 2024 GAAP EPS $(0.80) Misses $0.04 Estimate, Sales $152.177M Beat $113.850M Estimate

Mizuho analyst Vikram Malhorta maintains Essential Props Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Buy and raises the price target from $26 to $29.

EPRT

Mizuho Maintains Buy on Essential Props Realty, Raises Price Target to $29

Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 19.44 percent increase over losses of $(0.36) per share from the same period last year.

HUMA

Humacyte Q1 EPS $(0.29) Misses $(0.23) Estimate, Exits Quarter With Cash & Equivalents Worth $115.5M

Financial&nbsp;Outlook:
Based on information available as of May 10, 2024, for the&nbsp;second quarter&nbsp;of 2024 we expect:
<ul>
<li>Total revenue of&nbsp;$188&nbsp;to&nbsp;$189 million.</li>
<li>Adjusted EBITDA margin of&nbsp;37%&nbsp;to&nbsp;38%.</li>
<li>Non-GAAP diluted net income per share of&nbsp;$0.38&nbsp;to&nbsp;$0.40.</li>
<li>Fully diluted weighted average shares outstanding of approximately 102 to 103 million shares.</li>
</ul>
For the full year 2024, we expect:
<ul>
<li>Total revenue of&nbsp;$760&nbsp;to&nbsp;$775 million.</li>
<li>Adjusted EBITDA margin of&nbsp;36%&nbsp;to&nbsp;38%.</li>
<li>Adjusted free cash flow margin in the range of&nbsp;19%&nbsp;to&nbsp;21%&nbsp;of revenue.</li>
<li>Non-GAAP diluted net income per share of&nbsp;$1.60&nbsp;to&nbsp;$1.67.</li>
<li>Fully diluted weighted average shares outstanding of approximately 102 to 103 million shares.</li>
</ul>

DigitalOcean Holdings Expects Q2 Revenue of $188M-$189M Vs $187.09M Est, Adj EPS of $0.38-$0.40 Vs $0.39 Est

Sports

Media

INSE

Inspired Entertainment Launches NBA Re-Play Virtual Sports Product On Greece With OPAP

Needham analyst Charles Shi reiterates Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Hold.

Reiteration

ONTO

Needham Reiterates Hold on Onto Innovation

Mizuho analyst Haendel St. Juste maintains Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) with a Neutral and raises the price target from $60 to $62.

Mizuho Maintains Neutral on Agree Realty, Raises Price Target to $62

<a href="https://www.benzinga.com/topic/spot-bitcoin-etf">Bitcoin spot exchange-traded funds</a> (ETFs) saw net outflows of $11.29 million on May 9.
What Happened: The Grayscale Bitcoin Trust (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>) <a href="https://sosovalue.xyz/assets/us-btc-spot">registered</a> a substantial net outflow of $43.3522 million, while the BlackRock Bitcoin Trust (NASADAQ: IBIT) experienced a net inflow of $14.1946 million. Other ETFs also saw modest inflows:
<ul>
<li>Fidelity (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>): $3 million</li>
<li>Ark (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>): $4 million</li>
<li>Bitwise (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BITB#BATS">BITB</a>): $7 million</li>
<li>Invesco (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BTCO#BATS">BTCO</a>): $2 million</li>
</ul>
Analysts from QCP Capital indicated that the market is adjusting to the anticipations of two Federal Reserve rate cuts later this year, with the first cut expected no earlier than September.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38736514/donald-trump-says-you-better-vote-for-him-if-youre-pro-crypto-but-has-he-always-been-fine-">Donald Trump Says &#8216;You Better Vote&#8217; For Him If You&#8217;re Pro-Crypto: But Has He Always Been &#8216;Fine With It&#8217;?</a>
Why It Matters: Despite the outflows, there isn't a sense of bearish panic among traders.
Instead, the market is adapting to a scenario of lower volatility, with a structurally positive outlook on Bitcoin towards the year-end. 
Additionally, the U.S. Dollar has been on the rise, driven by expectations that other central banks may delay their rate cuts until after the Federal Reserve acts.
This cautious yet optimistic market sentiment aligns with the themes poised to be discussed at the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
The conference aims to delve into the dynamics of cryptocurrency investments and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38587443/what-the-fomc-meeting-means-for-bitcoins-next-move">broader economic factors</a> influencing these digital assets.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38733156/house-challenges-sec-over-crypto-custody-rules-biden-vows-blockade">House Challenges SEC Over Crypto Custody Rules, Biden Vows Blockade</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ARKB

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

Invesco Galaxy Bitcoin ETF Invesco Galaxy Bitcoin ETF

BTCO

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

GBTC

IBIT

Bitcoin Spot ETFs Collect $11.29M Net Inflows On Thursday

TBRG

TruBridge Q1 2024 Adj EPS $0.19 Beats $0.15 Estimate, Sales $83.247M Beat $83.013M Estimate

Mizuho analyst Siti Panigrahi upgrades Squarespace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQSP#NYSE">SQSP</a>) from Neutral to Buy and raises the price target from $34 to $50.

Upgrades

SQSP

Mizuho Upgrades Squarespace to Buy, Raises Price Target to $50

Replimune Group GAAP EPS of -$0.77 beats by $0.16

Replimune Group (REPL) has disclosed a new risk, in the Share Price & Shareholder Rights category. Replimune Group faces substantial risk as it pro...

Replimune Group Is Worried About This – Should You Be Worried Too?

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Omnicell (OMCL – Research Report), Replimune Group...

Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AstraZeneca (AZN – Research Report), Centessa Pharma...

Wall Street Analysts Are Bullish on Top Healthcare Picks

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Replimune Group (REPL – Research Report) today and set a price target of $12.00. Ro...

Positive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials

The market has been high on Replimune Group Inc (REPL)  stock recently. REPL gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Replimune Group Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on REPL!See Full REPL ReportWhat is Stock Sentiment?Senti

Is it Time to Dump Replimune Group Inc (REPL) Stock After it Is Up 14.79% in a Week?

Tracking Baker Brothers Portfolio - Q4 2023 Update

Replimune Group announces CEO transition

An announcement from Replimune Group Inc (REPL) is now available. Replimune Group, Inc. has announced a significant reshuffling of its executive te...

Replimune Group Announces Major Executive Team Overhaul

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Replimune Group (REPL – Research Report) and Merck &...

Analysts Are Bullish on Top Healthcare Stocks: Replimune Group (REPL), Merck & Company (MRK)

ABBV

ABCL

ACAD

ACHL

ADAP

AKRO

ALGS

ARGX

ATHA

AVTE

BCRX

BCYC

BGNE

BMEA

BMRN

CABA

CALA

CERS

CNTA

DNLI

GLUE

HOOK

HRTX

IMCR

IMTX

INCY

KYMR

MDGL

NRIX

OMCL

PAHC

RARE

ROIV

RVMD

RYTM

SGMT

TRDA

TSVT

ZYME

Press Releases

Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Replimune to Present at Three Upcoming Investor Conferences

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

Management

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

COYA

ENGN